A metanalysis published in BioMed Central's open access journal BMC Medicine has confirmed that polymorphisms (SNP) in the gene coding for interleukin-28 (IL28B) influence natural hepatitis C viral (HCV) clearance and response to pegylated interferon-α plus ribavirin (PEG-IFN/RBV). Information about IL28B genotype could be used to provide personalized medicine and target treatment options effectively.
Over 200 million people worldwide are chronically infected with hepatitis C virus (HCV) and about a quarter of these will go on to develop cirrhosis of the liver. Treatment with (PEG-IFN/RBV) only works in 40-80% of patients, depending in part on HCV strain, and treatment often has severe side effects. It is consequently important to separate people who will not respond to treatment, from those who may, so that treatment is targeted effectively.
Researchers from the Health Institute Carlos III, Spain, incorporated 67 studies that investigated IL28B polymorphisms with the suppression of viral activity to undetectable levels (sustained virologic response - SVR), and ten that looked at IL28B polymorphisms and spontaneous clearance, into a metanalysis. Approximately 23,500 people were included overall.
The results of this analysis showed that IL28B polymorphisms influence how well IFN treatment works and natural clearance of HCV infection. Having a favourable genotype at any one of seven IL28B polymorphisms equated to more than double the probability of achieving SVR. The study also found that two SNP were associated with spontaneous clearance. Detailed analysis showed that the effect of ethnicity and viral type also influenced the strength of individual association. Consequently the association between favourable variants and SVR for HCV types 2 and 3 was three times lower than types 1 and 4.
María Ángeles Jiménez-Sousa, Amanda Fernández-Rodríguez and Salvador Resino who led this study explained, "Treatment with (PEG-IFN/RBV) is costly and can have side effects which prevent patient compliance. Consequently knowing a patient's IL-28B status will help target interferon treatment to those who will benefit most, and play a substantial role in the selection of candidates for standard treatment versus triple therapy with direct-acting antivirals (DAA). Also, because IL28B genotyping needs be performed only once in a patient's life, it is relatively cheap."
BioMed Central: http://www.biomedcentral.com
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
The brain has a weak spot for Alzheimer's disease and schizophrenia, according to experts who have pinpointed the region using scans.
Scientists in California have captured the elusive anglerfish on film in its natural habitat, 1,900 feet below sea level
Researchers were shocked to discover multiple instances of seal-on-penguin rape
The tiny shrimp survive without sunlight and crawl within an inch of boiling hot waters
Birds are one of the most widely studied forms of life on the planet. And, there are still new species out there to discover — as one young researcher found recently in a forest in Indonesia.
About once a year, Florida harvester ants dig new nests, a mystery entomologists are eager to get to the bottom of.
The finding that male homosexuality has a strong genetic component should be a boon for gay rights – but it could backfire
Alan Turing, the man who pioneered computing, also forced the world to question what it means to be human
During sleep, the brain locks in existing memories and can even form new ones. Scientists say they are starting to understand how that happens. A midnight snack may interfere.
They walk among us. Natural experiments, living ordinary lives, unaware that their genes may hold the clue to the next superdrug.